What's GABA got to do with it? A potential link between the microbiome, schizophrenia, and the endo-cannabinoid...

Area of Science:

• Neuroscience
• Psychiatry
• Microbiology
• Metabolomics

Background:

• The gut microbiome is increasingly linked to neurological and psychiatric disorders, including schizophrenia.
• Investigating the microbiome's role in schizophrenia is challenging due to medication confounding factors in study participants.
• Understanding the interplay between medication, microbiome, and schizophrenia pathophysiology is crucial.

Purpose of the Study:

• To investigate specific microbial and metabolic alterations in schizophrenia patients.
• To account for the influence of medication, particularly GABA-enhancing drugs, on these alterations.
• To explore the connection between the microbiome, metabolic pathways, and schizophrenia.

Main Methods:

• Recruited 30 schizophrenia patients and 14 healthy controls.
• Collected fecal samples for microbiota analysis and serum samples for untargeted metabolome characterization.
• Analyzed data considering medication status, especially GABA-enhancers and antipsychotics.

Main Results:

• Significant differences in the microbiome were observed between schizophrenia patients and controls overall.
• Patients not on GABA-enhancing drugs showed microbiome profiles similar to controls.
• Metabolomic differences were also noted, with enriched citric acid cycle and amino acid biosynthesis pathways in patients on antipsychotics without GABA-enhancers.
• Exogenous GABA administration impacted overall patient homeostasis.

Conclusions:

• Medication, particularly GABA-enhancers, significantly influences the observed microbiome and metabolic alterations in schizophrenia.
• The gut microbiome plays a role in cognitive, emotional, and mental functions relevant to schizophrenia.
• Future research must consider the individual's medication status and overall physiological state when studying the microbiome's role in psychiatric disorders.